Working with the BGRU, we have conducted research into:
Recently, the research team has carried out tests of hormonal and non-hormonal therapies for the control of hot flushes, night sweats and sleep disturbance. We have also been engaged in a long-term study into the control of hot flushes to enhance quality of life following breast cancer treatment.
We have conducted studies into the efficacy and tolerability of new contraceptive devices and techniques, and trialled a new oral contraceptive pill. One of the contraceptive devices we developed and tested on 86 women over five years has been given FDA approval in the US.
Over a five-year longitudinal project (1000 women screened, 100 recruited) we studied the effect of hormone therapy on the occurrence of spinal fracture among post-menopausal women with osteoporosis. We have also done research into the efficacy of various drugs designed to prevent menopausal bone loss.
We have conducted several testosterone patch studies, a vaginal oestrogen study and a study of the effects of a non-hormonal therapy on vaginal dryness and painful sexual intercourse.
We are currently conducting pioneering research into the treatment of pelvic pain, uterine fibroids and endometriosis – including the development of an endometrial cell test, and a study of the efficacy of long-term use of botulinum toxin in relieving pelvic floor muscle spasm.
We have run studies of diabetes and weight loss, lipid-lowering agents, and the efficacy of complementary therapies in reducing anxiety.
If you’d like a full list of our research publications, please see our Research Team.
WHRIA has been at the forefront of the development of a number of new, innovative methods for treating different aspects of women’s health.
We trialled a new female sterilisation method that uses the Adiana trans-cervical device. EASE is a multi-centre, prospective evaluation of the Adiana System for trans-cervical sterilization using electro-thermal energy, in women aged 18-45.
We tested the safety and preliminary efficacy of the Miniaturo™-I system for the treatment of patients with urinary urge incontinence.
We conducted a preliminary safety and efficacy study into the VizAblate system for the treatment of uterine fibroid tumors.
With this study, we defined the pharmacokinetic properties of lignocaine gel applied topically for minor gynaecological procedures.
If you have a specific enquiry for our WHRIA specialistsClick Here